270 related articles for article (PubMed ID: 20297868)
1. Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection.
Haas MJ; Mooradian AD
Drugs; 2010 May; 70(7):805-21. PubMed ID: 20297868
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.
Maïga SF; Kalopissis AD; Chabert M
Biochimie; 2014 Jan; 96():56-66. PubMed ID: 24012775
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapeutic strategies to enhance HDL function.
Redondo S; Martínez-González J; Urraca C; Tejerina T
Lipids Health Dis; 2011 Oct; 10():175. PubMed ID: 21985435
[TBL] [Abstract][Full Text] [Related]
4. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.
Tuteja S; Rader DJ
Clin Pharmacol Ther; 2014 Jul; 96(1):48-56. PubMed ID: 24713591
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits.
Shimoji E; Zhang B; Fan P; Saku K
Atherosclerosis; 2004 Feb; 172(2):247-57. PubMed ID: 15019534
[TBL] [Abstract][Full Text] [Related]
6. Targeting high-density lipoproteins: update on a promising therapy.
Verdier C; Martinez LO; Ferrières J; Elbaz M; Genoux A; Perret B
Arch Cardiovasc Dis; 2013 Nov; 106(11):601-11. PubMed ID: 24074699
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.
Qin S; Koga T; Ganji SH; Kamanna VS; Kashyap ML
Metabolism; 2008 Jul; 57(7):973-9. PubMed ID: 18555840
[TBL] [Abstract][Full Text] [Related]
8. High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases.
Ikenaga M; Higaki Y; Saku K; Uehara Y
J Atheroscler Thromb; 2016; 23(4):385-94. PubMed ID: 26830201
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach.
Gadkar K; Lu J; Sahasranaman S; Davis J; Mazer NA; Ramanujan S
J Lipid Res; 2016 Jan; 57(1):46-55. PubMed ID: 26522778
[TBL] [Abstract][Full Text] [Related]
10. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice.
Hayek T; Ito Y; Azrolan N; Verdery RB; Aalto-Setälä K; Walsh A; Breslow JL
J Clin Invest; 1993 Apr; 91(4):1665-71. PubMed ID: 8473509
[TBL] [Abstract][Full Text] [Related]
11. Recombinant high-density lipoproteins and their use in cardiovascular diseases.
Cao YN; Xu L; Han YC; Wang YN; Liu G; Qi R
Drug Discov Today; 2017 Jan; 22(1):180-185. PubMed ID: 27591840
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of HDL in cardioprotection and tissue repair.
Van Linthout S; Frias M; Singh N; De Geest B
Handb Exp Pharmacol; 2015; 224():527-65. PubMed ID: 25523001
[TBL] [Abstract][Full Text] [Related]
13. [High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning].
Kleber ME; Grammer TB; März W
MMW Fortschr Med; 2010 Jul; 152 Suppl 2():47-55. PubMed ID: 21591319
[TBL] [Abstract][Full Text] [Related]
14. The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.
Namiri-Kalantari R; Gao F; Chattopadhyay A; Wheeler AA; Navab KD; Farias-Eisner R; Reddy ST
Biofactors; 2015 May; 41(3):153-9. PubMed ID: 26072738
[TBL] [Abstract][Full Text] [Related]
15. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels.
Hayek T; Chajek-Shaul T; Walsh A; Agellon LB; Moulin P; Tall AR; Breslow JL
J Clin Invest; 1992 Aug; 90(2):505-10. PubMed ID: 1644921
[TBL] [Abstract][Full Text] [Related]
16. [New trends in lipidology: the increasing role of HDL-cholesterol].
Paragh G; Harangi M; László M
Orv Hetil; 2008 Jul; 149(30):1395-404. PubMed ID: 18621598
[TBL] [Abstract][Full Text] [Related]
17. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice.
Hayek T; Azrolan N; Verdery RB; Walsh A; Chajek-Shaul T; Agellon LB; Tall AR; Breslow JL
J Clin Invest; 1993 Sep; 92(3):1143-52. PubMed ID: 8376576
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI.
Atger V; de la Llera Moya M; Bamberger M; Francone O; Cosgrove P; Tall A; Walsh A; Moatti N; Rothblat G
J Clin Invest; 1995 Dec; 96(6):2613-22. PubMed ID: 8675626
[TBL] [Abstract][Full Text] [Related]
19. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
20. Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance.
Mooradian AD; Haas MJ
Drugs; 2015 May; 75(7):713-22. PubMed ID: 25895465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
